No apparent impact of incremental dosing on eliciting dose at double-blind, placebo-controlled peanut challenge

Allergy. 2022 Feb;77(2):667-670. doi: 10.1111/all.15130. Epub 2021 Oct 10.

Authors

Olaya Álvarez García^{1

2}, Joan Bartra^{1

3}, Monica Ruiz-Garcia¹, Isabel J Skypala^{1

4}, Stephen R Durham^{1

4}, Robert J Boyle¹, E N Clare Mills⁵, Paul J Turner¹

Affiliations

¹ National Heart & Lung Institute, Imperial College London, London, UK.
² Complexo Hospitalario Universitario de Ferrol, A Coruña, Spain.
³ Hospital Clínic de Barcelona, Barcelona, Spain.
⁴ Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
⁵ Division of Infection, Immunity & Respiratory Medicine, Manchester Institute of Biotechnology, University of Mancheste, Manchester, UK.

PMID: 34614236
DOI: 10.1111/all.15130

No abstract available

Keywords: allergy; eliciting dose; food challenge; lowest observed adverse effect level; peanut.

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Allergens
Arachis* / adverse effects
Desensitization, Immunologic
Double-Blind Method
Humans
Peanut Hypersensitivity* / diagnosis

Substances

Allergens

Grants and funding